LIPOCINE INC (LPCN) Fundamental Analysis & Valuation

NASDAQ:LPCN • US53630X2036

Current stock price

2.37 USD
-0.05 (-2.07%)
Last:

This LPCN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LPCN Profitability Analysis

1.1 Basic Checks

  • LPCN had negative earnings in the past year.
  • LPCN had a negative operating cash flow in the past year.
  • LPCN had negative earnings in 4 of the past 5 years.
  • In the past 5 years LPCN always reported negative operating cash flow.
LPCN Yearly Net Income VS EBIT VS OCF VS FCFLPCN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -56.61%, LPCN is doing worse than 68.06% of the companies in the same industry.
  • With a Return On Equity value of -66.50%, LPCN perfoms like the industry average, outperforming 42.93% of the companies in the same industry.
Industry RankSector Rank
ROA -56.61%
ROE -66.5%
ROIC N/A
ROA(3y)-42.56%
ROA(5y)-31.51%
ROE(3y)-48.91%
ROE(5y)-35.66%
ROIC(3y)N/A
ROIC(5y)N/A
LPCN Yearly ROA, ROE, ROICLPCN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for LPCN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LPCN Yearly Profit, Operating, Gross MarginsLPCN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. LPCN Health Analysis

2.1 Basic Checks

  • LPCN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LPCN has more shares outstanding
  • The number of shares outstanding for LPCN has been increased compared to 5 years ago.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LPCN Yearly Shares OutstandingLPCN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
LPCN Yearly Total Debt VS Total AssetsLPCN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -13.93, we must say that LPCN is in the distress zone and has some risk of bankruptcy.
  • LPCN's Altman-Z score of -13.93 is on the low side compared to the rest of the industry. LPCN is outperformed by 80.63% of its industry peers.
  • There is no outstanding debt for LPCN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -13.93
ROIC/WACCN/A
WACC9.58%
LPCN Yearly LT Debt VS Equity VS FCFLPCN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • LPCN has a Current Ratio of 6.68. This indicates that LPCN is financially healthy and has no problem in meeting its short term obligations.
  • LPCN has a Current ratio of 6.68. This is in the better half of the industry: LPCN outperforms 72.25% of its industry peers.
  • A Quick Ratio of 6.68 indicates that LPCN has no problem at all paying its short term obligations.
  • LPCN has a Quick ratio of 6.68. This is in the better half of the industry: LPCN outperforms 72.25% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 6.68
LPCN Yearly Current Assets VS Current LiabilitesLPCN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. LPCN Growth Analysis

3.1 Past

  • LPCN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -214.94%.
  • Looking at the last year, LPCN shows a very negative growth in Revenue. The Revenue has decreased by -82.35% in the last year.
  • Measured over the past years, LPCN shows a very strong growth in Revenue. The Revenue has been growing by 58.12% on average per year.
EPS 1Y (TTM)-214.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.58%
Revenue 1Y (TTM)-82.35%
Revenue growth 3Y58.12%
Revenue growth 5YN/A
Sales Q2Q%-67.17%

3.2 Future

  • LPCN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.73% yearly.
  • The Revenue is expected to grow by 145.40% on average over the next years. This is a very strong growth
EPS Next Y-25.92%
EPS Next 2Y18.11%
EPS Next 3Y14.73%
EPS Next 5YN/A
Revenue Next Year-32.9%
Revenue Next 2Y13.5%
Revenue Next 3Y38.48%
Revenue Next 5Y145.4%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
LPCN Yearly Revenue VS EstimatesLPCN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 20M 40M 60M 80M
LPCN Yearly EPS VS EstimatesLPCN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

0

4. LPCN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LPCN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LPCN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LPCN Price Earnings VS Forward Price EarningsLPCN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LPCN Per share dataLPCN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • LPCN's earnings are expected to grow with 14.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.11%
EPS Next 3Y14.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LPCN Dividend Analysis

5.1 Amount

  • LPCN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LPCN Fundamentals: All Metrics, Ratios and Statistics

LIPOCINE INC

NASDAQ:LPCN (4/27/2026, 3:51:48 PM)

2.37

-0.05 (-2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-10
Earnings (Next)05-06
Inst Owners23.29%
Inst Owner Change4.1%
Ins Owners2.5%
Ins Owner Change34.27%
Market Cap17.30M
Revenue(TTM)1.98M
Net Income(TTM)-9.63M
Analysts82.5
Price Target11.22 (373.42%)
Short Float %2.02%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.69%
Min EPS beat(2)-7.12%
Max EPS beat(2)32.5%
EPS beat(4)2
Avg EPS beat(4)6.71%
Min EPS beat(4)-7.12%
Max EPS beat(4)32.5%
EPS beat(8)6
Avg EPS beat(8)102.92%
EPS beat(12)7
Avg EPS beat(12)55.58%
EPS beat(16)10
Avg EPS beat(16)38.19%
Revenue beat(2)1
Avg Revenue beat(2)407.97%
Min Revenue beat(2)-52.63%
Max Revenue beat(2)868.56%
Revenue beat(4)2
Avg Revenue beat(4)227.14%
Min Revenue beat(4)-74.1%
Max Revenue beat(4)868.56%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.15%
PT rev (3m)60%
EPS NQ rev (1m)8.49%
EPS NQ rev (3m)19.17%
EPS NY rev (1m)-20.72%
EPS NY rev (3m)-20.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.75
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-1.77
EYN/A
EPS(NY)-2.23
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.27
BVpS1.98
TBVpS1.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -56.61%
ROE -66.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.56%
ROA(5y)-31.51%
ROE(3y)-48.91%
ROE(5y)-35.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 6.68
Altman-Z -13.93
F-Score1
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-214.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-122.58%
EPS Next Y-25.92%
EPS Next 2Y18.11%
EPS Next 3Y14.73%
EPS Next 5YN/A
Revenue 1Y (TTM)-82.35%
Revenue growth 3Y58.12%
Revenue growth 5YN/A
Sales Q2Q%-67.17%
Revenue Next Year-32.9%
Revenue Next 2Y13.5%
Revenue Next 3Y38.48%
Revenue Next 5Y145.4%
EBIT growth 1Y-800.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-644.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-699.27%
OCF growth 3YN/A
OCF growth 5YN/A

LIPOCINE INC / LPCN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LIPOCINE INC (LPCN) stock?

ChartMill assigns a fundamental rating of 3 / 10 to LPCN.


What is the valuation status for LPCN stock?

ChartMill assigns a valuation rating of 0 / 10 to LIPOCINE INC (LPCN). This can be considered as Overvalued.


How profitable is LIPOCINE INC (LPCN) stock?

LIPOCINE INC (LPCN) has a profitability rating of 0 / 10.


What is the financial health of LIPOCINE INC (LPCN) stock?

The financial health rating of LIPOCINE INC (LPCN) is 6 / 10.


What is the expected EPS growth for LIPOCINE INC (LPCN) stock?

The Earnings per Share (EPS) of LIPOCINE INC (LPCN) is expected to decline by -25.92% in the next year.